Burgstaler Edwin A, Porrata Luis F, Markovic Svetomir N, Winters Jeffrey L
Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Clin Apher. 2010;25(6):301-9. doi: 10.1002/jca.20259. Epub 2010 Sep 7.
Autologous HPC collection focus has been CD34+ cell yield but product content of other cells is important for patient survival, complications, and resource utilization.
Prospective, paired study examining MNC and RBC offsets (opens and closes collect valve, respectively) was performed using Fenwal Amicus. Lymphocyte, CD34+ cell yields, and cross-cellular contamination were compared using different MNC/RBC offsets and retrospective Spectra data.
In paired comparisons, median lymphocyte yields were significantly different only between 0.0/7.0 (17.6 × 10(9)) and 1.5/5.0 (14.5 × 10(9)) offsets. CD34+ yields were not significantly different between offsets except 1.0/7.0 and 1.5/5.0 (230.3 vs. 156.7 × 10(6)). Granulocytes, RBC, and PLT were significantly greater with higher RBC offset. Comparing all offsets, 1.5/5.0 collected fewer lymphocytes, granulocytes, RBC, and PLT. 1.5/6.0 offsets collected more lymphocytes than 1.5/5.0 but fewer granulocytes and RBC than others except 1.5/5.0. For 1.5/6.0 offsets, PLT content was higher than 1.5/5.0, equivalent to the other offsets, and less than Spectra. CD34+ yields for 1.5/6.0 offsets were equivalent to others except 1.0/7.0. Manufacturer's default (2.3/6.8) collected equivalent lymphocytes and CD34+ to all offsets (except 1.0/7.0) and Spectra. Cross-cellular contamination was higher than 1.5/5.0 and 1.5/6.0 but equivalent to others with more RBC and fewer PLT than Spectra.
For maximum lymphocyte yield and minimum contamination, 1.5/6.0 offsets appear optimal. For minimum lymphocyte yield and contamination, 1.5/5.0 offsets would be preferred. Manufacturer's default has CD34+ cell and lymphocyte yields similar to 1.5/6.0 with greater contamination. Amicus can achieve lymphocyte and CD34+ yields similar to Spectra but has significantly less PLT removal.
自体造血干细胞采集的重点一直是CD34+细胞产量,但其他细胞的产品含量对患者生存、并发症及资源利用也很重要。
使用费森尤斯阿密克斯进行前瞻性配对研究,检测单核细胞(MNC)和红细胞(RBC)补偿量(分别打开和关闭采集阀)。采用不同的MNC/RBC补偿量及回顾性的光谱数据比较淋巴细胞、CD34+细胞产量及跨细胞污染情况。
在配对比较中,仅0.0/7.0(17.6×10⁹)和1.5/5.0(14.5×10⁹)补偿量之间的淋巴细胞产量中位数有显著差异。除1.0/7.0和1.5/5.0(230.3对156.7×10⁶)外,各补偿量之间的CD34+产量无显著差异。红细胞补偿量越高,粒细胞、红细胞和血小板含量越高。比较所有补偿量,1.5/5.0采集的淋巴细胞、粒细胞、红细胞和血小板较少。1.5/6.0补偿量采集的淋巴细胞比1.5/5.0多,但粒细胞和红细胞比除1.5/5.0外的其他补偿量少。对于1.5/6.0补偿量,血小板含量高于1.5/5.0,与其他补偿量相当,且低于光谱法采集的量。1.5/6.0补偿量的CD34+产量与除1.0/7.0外的其他补偿量相当。制造商默认的补偿量(2.3/6.8)采集的淋巴细胞和CD34+与所有补偿量(除1.0/7.0)及光谱法采集的量相当。跨细胞污染高于1.5/5.0和1.5/6.0,但与其他补偿量相当,红细胞比光谱法多,血小板比光谱法少。
为获得最大淋巴细胞产量和最小污染,1.5/6.0补偿量似乎最佳。为获得最小淋巴细胞产量和污染,1.5/5.0补偿量更可取。制造商默认的补偿量的CD34+细胞和淋巴细胞产量与1.5/6.0相似,但污染更大。阿密克斯能获得与光谱法相似的淋巴细胞和CD34+产量,但血小板去除量明显更少。